• Protagonist Therapeutics swung to GAAP net income of USD 162.85 million in Q2 2026 from a loss a year earlier; diluted EPS was USD 2.29.
• GAAP revenue climbed to USD 213.48 million from USD 5.55 million, driven mainly by Takeda opt-out payment recognition and development services.
• GAAP R&D expense rose to USD 42.06 million from USD 37.04 million; GAAP G&A increased to USD 12.65 million from USD 10.55 million.
• Cash, cash equivalents and marketable securities rose to USD 849.45 million at June 30 from USD 646 million at Dec. 31.
• Rusfertide NDA remained under FDA priority review with an August 2026 PDUFA date; ICOTYDE posted its first full quarter of commercial sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Protagonist Therapeutics Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 202608051605ACCESSWRNAPR_____1202122) on August 05, 2026, and is solely responsible for the information contained therein.